## Remarks

Claims 2, 4-6 and 9 of the present application are pending. Claims 3, 7-8, and 10-17 have been cancelled. Claim 2 has been amended. More specifically, the subject matter of claim 8 has been incorporated into claim 2.

## Election/Restriction

Applicants wish to provisionally elect Group I, which are claims 2, 4 and 5-9, drawn to a combination. Applicants reserve the right to file divisional applications pertaining to the subject matter in Groups II and III.

## **Election of Species**

Applicants wish to elect the radioimmunoconjugate <sup>131</sup>I-CC49. Entry of this Response is respectfully requested.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7852

Date: /2/20/07

Oona A. Manzari

Attorney for Applicants

Reg. No. 48,152